Welcome to our dedicated page for INSULET SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INSULET's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INSULET's regulatory disclosures and financial reporting.
Benjamin Eric, Executive Vice President and Chief Product Experience Officer at Insulet Corporation (PODD), reported the sale of 4,263 shares of Insulet common stock on 08/21/2025 at a price of $332.23 per share. Following the transaction, he beneficially owns 16,736 shares. The Form 4 indicates the sale was made pursuant to an existing Rule 10b5-1 trading plan. The filing also notes that 93 shares were acquired through the company Employee Stock Purchase Plan since his last Form 4. The document is a routine Section 16 disclosure of an insider sale under a pre-established plan and does not disclose additional transactions, derivatives, or other compensatory details.
Michael R. Minogue, a director of Insulet Corporation (PODD), reported multiple transfers of common stock on 08/19/2025 and 08/21/2025. The Form 4 shows transfers described as coming from a GRAT and as bona fide gifts to a trust for the reporting person’s spouse, who is trustee. The filing lists several paired dispositions and acquisitions of 9,459 and 1,380 shares (transaction code G, gift/transfer). The report discloses post-transaction beneficial ownership amounts including 778 shares held directly and 15,453 shares held indirectly by trust, along with intermediate reported balances (e.g., 11,617, 14,073). The signature is by attorney-in-fact John W. Kapples dated 08/21/2025.
Insulet Corporation (PODD) Form 144 reports a proposed sale of 4,263 shares of common stock through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $1,416,296.49 and an approximate sale date of 08/21/2025. The filing shows the shares to be sold were recently acquired by the seller through restricted stock vesting on 02/14/2025 (2,842 shares), 02/27/2025 (806 shares), and 02/28/2025 (615 shares), with consideration recorded as compensation. No securities were reported sold by the same person in the prior three months. The filer attests they are not aware of any undisclosed material adverse information about the issuer.
Capital Research Global Investors reports beneficial ownership of 4,736,127 shares of Insulet Corporation, equal to 6.7% of the company's outstanding common stock. The filing shows sole voting power for 4,730,490 shares and sole dispositive power for 4,736,127 shares, with no shared voting or dispositive authority reported.
The statement classifies the filer as an investment adviser and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. This is a routine institutional ownership disclosure reflecting a material passive stake above the 5% threshold.
Insulet Corporation insider report: Prem Singh, SVP, Global Operations, reported multiple equity transactions dated 08/07/2025 involving common stock and stock options of Insulet (PODD). The Form 4 shows two acquisitions of common stock for 585 shares at $264.69 and 758 shares at $276.36, and a disposition of 1,343 shares sold at $320. The filing states these transactions were effected under an existing Rule 10b5-1 trading plan. The report also discloses annual non-qualified stock option awards: 585 options at a $264.69 exercise price (expiring 02/28/2032) and 758 options at a $276.36 exercise price (expiring 02/28/2033), each vesting in substantially equal installments over four years. The document lists line-by-line beneficial ownership figures corresponding to each transaction.